Tasigna and Erysipelas - a phase IV clinical study of FDA data

Summary:

Erysipelas is reported as a side effect among people who take Tasigna (nilotinib hydrochloride monohydrate), especially for people who are male, 60+ old, have been taking the drug for 1 - 6 months also take Hydrea, and have Gastrointestinal stromal tumor.

The phase IV clinical study analyzes which people have Erysipelas when taking Tasigna. It is created by eHealthMe based on reports of 31,413 people who have side effects when taking Tasigna from the FDA, and is updated regularly.

What is Tasigna?

Tasigna has active ingredients of nilotinib hydrochloride monohydrate. It is often used in chronic myelogenous leukemia (cml). eHealthMe is studying from 31,535 Tasigna users. Check the latest studies of Tasigna.

What is Erysipelas?

Erysipelas (bacterial skin infection) is found to be associated with 452 drugs and 644 conditions by eHealthMe. Check the latest studies of Erysipelas.

On Jul, 18, 2026

31,413 people reported to have side effects when taking Tasigna.
Among them, 13 people (0.04%) have Erysipelas.

Among these 13 people:

How long have people been on Tasigna when they have Erysipelas? *

What is the gender of people who have Erysipelas when taking Tasigna? *

female: 50 %
male: 50 %

What is the age of people who have Erysipelas when taking Tasigna? *

What are other drugs people take besides Tasigna? *

Hydrea: 3 people, 23.08%
Pantoprazole: 1 person, 7.69%
Movicol: 1 person, 7.69%
Metformin: 1 person, 7.69%
Lasix: 1 person, 7.69%
Glivec: 1 person, 7.69%
Euthyrox: 1 person, 7.69%
Diclofenac: 1 person, 7.69%
Candesartan Cilexetil And Hydrochlorothiazide: 1 person, 7.69%
Calcium: 1 person, 7.69%

What are other side effects people have besides Erysipelas? *

Itching: 4 people, 30.77%
Dermatitis Bullous (inflammation of the skin characterized by the presence of bullae which are filled with fluid): 4 people, 30.77%
Tinnitus (a ringing in the ears): 4 people, 30.77%
Rashes (redness): 4 people, 30.77%
High Blood Cholesterol: 4 people, 30.77%
Headache (pain in head): 3 people, 23.08%
Haematocrit Decreased: 3 people, 23.08%
Fever: 3 people, 23.08%
Electrocardiogram Qt Prolonged: 3 people, 23.08%
Eczema (patches of skin become rough and inflamed, with itching and bleeding blisters): 3 people, 23.08%

What are the existing conditions these people have? *

Hyperlipidaemia (presence of excess lipids in the blood): 4 people, 30.77%
Gastrointestinal Stromal Tumor: 4 people, 30.77%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 2 people, 15.38%
Hyperuricaemia (level of uric acid in the blood that is abnormally high): 2 people, 15.38%
Restless Leg Syndrome (a powerful urge to move your legs): 1 person, 7.69%
Rashes (redness): 1 person, 7.69%
Pain: 1 person, 7.69%
Nasopharyngitis (inflammation of the nasopharynx): 1 person, 7.69%
Hypokalemia (low potassium): 1 person, 7.69%
Hypocalcaemia (levels of calcium in blood serum are abnormally low): 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Tasigna and have Erysipelas?

- Check whether Erysipelas is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Tasigna:

Tasigna (31,535 reports)

Erysipelas treatments and more:

Erysipelas (8,077 reports)

How severe was Erysipelas and when was it recovered:

Erysipelas in Tasigna

Expand to all the drugs that have ingredients of nilotinib hydrochloride monohydrate:

Erysipelas and drugs with ingredients of nilotinib hydrochloride monohydrate

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Tasigna:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Erysipelas:

Erysipelas (452 drugs)

Browse all the conditions that are associated with Erysipelas:

Erysipelas (644 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on nilotinib hydrochloride monohydrate (the active ingredients of Tasigna) and Tasigna (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.